Oncology
Latest news
915 articles · 20 / page
Stereotactic Radiation Preserves Quality of Life Over Hippocampal-Avoidance Whole Brain Radiation in Patients with 5 to 20 Brain Metastases
A Phase 3 randomized trial reveals that stereotactic radiation significantly outperforms hippocampal-avoidance whole brain radiation in reducing symptom severity and interference with daily living for patients with 5 to 20 brain metastases,
Timing the Tactic: SONIA Trial Finds No Survival Advantage for First-Line vs. Second-Line CDK4/6 Inhibition in Advanced Breast Cancer
The phase 3 SONIA trial demonstrates that initiating CDK4/6 inhibitors in the first-line setting does not improve overall survival compared to second-line use in HR-positive, ERBB2-negative advanced breast cancer, while significantly increa
Serplulimab Plus Chemotherapy Redefines First-Line Standards in Non-Squamous NSCLC: Results from the ASTRUM-002 Trial
The Phase 3 ASTRUM-002 trial demonstrates that adding serplulimab to chemotherapy significantly extends progression-free survival in non-squamous NSCLC, though the further addition of a bevacizumab biosimilar (HLX04) did not provide statist
Aumolertinib Transforms Adjuvant Treatment for EGFR-Mutated Lung Cancer: Significant Survival Gains in the Phase 3 ARTS Trial
The Phase 3 ARTS trial demonstrates that adjuvant aumolertinib significantly improves disease-free survival in patients with resected stage II-IIIB EGFR-mutated NSCLC, reducing the risk of recurrence or death by 83% compared to placebo, wit
Breaking Resistance in Gynaecological Clear Cell Carcinoma: Pembrolizumab plus Lenvatinib Achieves 40% Response Rate in LARA Trial
The Phase 2 LARA trial demonstrates that combining pembrolizumab and lenvatinib yields a 40% objective response rate in recurrent gynaecological clear cell carcinoma, offering a potential new standard for this historically chemo-resistant a
Cabozantinib Plus Temozolomide: A Promising Dual-Pathway Approach for Advanced Leiomyosarcoma
A phase 2 trial demonstrates that combining cabozantinib with temozolomide provides significant progression-free survival benefits for patients with advanced leiomyosarcoma, achieving a 74% 12-week PFS rate with a manageable safety profile,
Integrating Patient-Reported Outcomes Significantly Enhances the Reliability of Toxicity Assessments in Cancer Trials
A multinational randomized trial demonstrates that providing oncologists with patient-reported outcome data significantly improves the inter-rater reliability of CTCAE ratings for symptomatic adverse events, addressing a long-standing gap i
Metastasis-Directed Therapy Delivers Clear Progression Benefits in Oligometastatic Prostate Cancer: The WOLVERINE IPD Meta-Analysis
The WOLVERINE individual patient data meta-analysis confirms that metastasis-directed therapy significantly improves progression-free and castration resistance-free survival in oligometastatic prostate cancer, providing high-level evidence
Closing the Gap: How Equitably Applying Minimally Invasive Surgery Could Transform Colon Cancer Outcomes
A population-based study in England reveals that correcting socioeconomic and clinical inequalities in the use of minimally invasive surgery for colon cancer significantly reduces hospital stays and 1-year mortality, highlighting a critical
Systematic Complication Management Boosts Long-Term Survival in Pancreatic Cancer: Insights from the PORSCH Trial
A post-hoc analysis of the nationwide PORSCH trial reveals that algorithm-based care for early recognition and management of postoperative complications significantly improves long-term overall survival in patients undergoing pancreatic res
AI-Driven Detection of Extranodal Extension Outperforms Radiologists in Predicting Outcomes for HPV-Positive Oropharyngeal Cancer
A single-center study demonstrates that an AI pipeline for CT-based lymph node segmentation and extranodal extension classification significantly improves prognostic accuracy for HPV-positive oropharyngeal cancer compared to traditional rad
Breaking the Cycle of Exclusion: How Cultural Capital and Stigma Hinder Hospice Access for Low-Income Patients
A qualitative study published in JAMA Network Open identifies how limited cultural capital, cancer-related stigma, and economic deprivation form a self-reinforcing cycle that excludes low-income patients from hospice care, highlighting the
Safety First: Concurrent Metastases-Directed Stereotactic Radiotherapy and Biological Therapy Show Low Risk of Severe Adverse Events
A prospective multicenter study of 433 patients demonstrates that combining stereotactic radiotherapy with biological cancer therapy is safe, with severe adverse events occurring in less than 10% of cases. Crucially, continuing biological t
Environmental Cardiotoxicity: PM2.5 and Ozone Exposure Double the Risk of Cardiac Dysfunction in Breast Cancer Patients
A prospective study reveals that PM2.5 and ozone exposure significantly exacerbate cardiac dysfunction and adverse remodeling in breast cancer patients receiving anthracyclines or trastuzumab, doubling the risk of clinical LVEF decline.
Docetaxel Rechallenge vs Cabazitaxel: Choosing the Right Taxane Sequence in Metastatic Castration-Resistant Prostate Cancer
A retrospective cohort study of 669 veterans suggests that docetaxel rechallenge provides a significant survival benefit compared to cabazitaxel for patients with metastatic castration-resistant prostate cancer who previously responded to d
Moving Beyond Birthdays: Five-Year Absolute Risk-Based Screening Outperforms Age-Based Mammography
A CISNET modeling study demonstrates that mammography screening tailored to 5-year absolute invasive breast cancer risk reduces false-positive recalls by up to 23% while maintaining or improving mortality benefits compared to traditional ag
A Proactive Approach to Ovarian Cancer: The New ESGO Consensus on Opportunistic Salpingectomy
The European Society of Gynaecological Oncology (ESGO) has released new consensus statements advocating for opportunistic salpingectomy—removing fallopian tubes during unrelated surgeries—to significantly reduce ovarian cancer risk without
Low Baseline PSA Predicts Exceptional Long-Term Safety: A 20-Year Paradigm Shift in Prostate Cancer Screening
A 20-year cohort study shows that baseline PSA levels in men aged 45-70 are highly predictive of long-term prostate cancer risk, with PSA
Opportunistic Bilateral Salpingectomy Reduces Serous Ovarian Cancer Risk by Nearly 80 Percent
A large-scale population study confirms that removing fallopian tubes during unrelated pelvic surgeries reduces serous ovarian cancer risk by 78%, providing robust evidence for its use as a primary prevention strategy against high-grade ser
Hidden Reservoirs: Six Decades of Autopsy Data Reveal the Growing Burden of Undiagnosed Cancer
A 66-year Japanese autopsy study reveals a significant reservoir of undiagnosed latent cancers, highlighting rising multiple primary cancer rates and substantial over-prevalence in prostate and thyroid tissues compared to clinical data, emp
Browse by specialty
Open language-specific specialty feeds and department pages.